Cerro Pacific Wealth Advisors’s Intellia Therapeutics NTLA Stock Holding History

Cerro Pacific Wealth Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$169K	Buy	+10,000	New	+$140K	0.04%	163

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Cerro Pacific Wealth Advisors's NTLA Position: Q2 2026 in Review

Cerro Pacific Wealth Advisors opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 10,000 shares worth $169K. The stake represents 0.04% of the portfolio and ranks #163 among its holdings.

327 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Cerro Pacific Wealth Advisors held 10,000 shares of Intellia Therapeutics worth $169K as of Q2 2026.
Intellia Therapeutics was a new Cerro Pacific Wealth Advisors position in Q2 2026.
Intellia Therapeutics made up 0.04% of Cerro Pacific Wealth Advisors's portfolio in Q2 2026, its #163 holding.
327 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Cerro Pacific Wealth Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.